Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGAM1 | P18669 | 8/20 | 0.73 |
| ▸ | PKLR | P30613 | 12/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.71 |
| ▸ | BCL2 | P10415 | 1/20 | 0.62 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.62 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alizarin Red SCHEMBL29372853 | 0.85 | PGAM1 (1.00) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL1203855 | 0.85 | PGAM1 (1.00) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL29630358 | 0.85 | PGAM1 (1.00) | PGAM1PKLRPTPN1BCL2MCL1 | |
| SCHEMBL1506814 | 0.83 | PGAM1 (0.73) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL433811 | 0.83 | PGAM1 (0.97) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL728495 | 0.83 | PGAM1 (0.97) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL27607379 | 0.83 | PGAM1 (0.97) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL728494 | 0.82 | PKLR (1.00) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL29368828 | 0.82 | PKLR (1.00) | PGAM1PKLRPTPN1BCL2MCL1 | |
| Alizarin Red SCHEMBL29349481 | 0.82 | PKLR (1.00) | PGAM1PKLRPTPN1BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895725-B2 | Use of 9, 10-anthraquinone compounds | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-11-25 | — | — | US | disclosed |
| US-20110224414-A1 | USE OF 9, 10-ANTHRAQUINONE COMPOUNDS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224414-A1 | USE OF 9, 10-ANTHRAQUINONE COMPOUNDS | HCCS, CYC1, C1S | PGAM1 4080/4885PKLR 3805/4885PTPN1 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.